Ayman Wahbeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayman Wahbeh has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Izzat AlAwwa
School of Medicine, The University of Jordan, Amman 11942, Jordan
4 shared publications - Hussein Alhawari
School of Medicine, The University of Jordan, Amman 11942, Jordan
3 shared publications - Nailya Bulatova
School of Pharmacy, The University of Jordan, Amman 11942, Jordan
3 shared publications - Sameeha Alshelleh
Division of Nephrology, Department of Medicine, The University of Jordan, Amman, Jordan
3 shared publications - Ashraf O. Oweis
School of Medicine, Jordan University of Science and Technology, Ramtha 22110, Jordan
2 shared publications Dalia Abdelrazaq
Department of Pharmacology, School of Medicine, The University of Jordan, Amman, 11942, Jordan
2 shared publications
Latest Publications
- 9 March 2026
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 22 (3) , 1-6
The Variability of Response to Amlodipine and Its Relation with the Angiotensinogen M235T Genotype among a Sample of Hypertensive Patients in Jordan
Introduction: Amlodipine, a calcium channel blocker, is widely used to treat hyperten-sion, but its effectiveness varies among individuals. Clinicians have observed this variability, and previous research suggests that the Angiotensinogen (AGT) M235T genotype influences response to antihypertensive drugs like valsartan. This study investigates the association between the AGT M235T genetic variant and non-genetic anthropometric factors, and the response to amlodipine in essential hypertensive patients at the University of Jordan Hospital. Methods: A cohort of 46 unrelated Arabic Jordanian patients with essential hypertension was en-rolled. Baseline systolic and diastolic blood pressure (BP) readings were recorded before initiating 5 mg amlodipine, with follow-up measurements taken after one month. AGT M235T genotyping was performed using PCR-RFLP, and non-genetic data were obtained from hospital records. Results: It was found that 28.3% of the tested patients did not respond to amlodipine. The hetero-zygous AGT M235T genotype showed a significantly (p < 0.05, t-test) lower reduction in the BP compared to wild-type carriers, and its frequency was significantly higher (p < 0.05, ꭙ2 test) among the non-responders to amlodipine. In addition, the average age of the non-responders (41.5±10.3 years) was significantly (p < 0.05, t-test) lower than that of responders (47±10 years) to amlodipine. Discussion: The heterozygous AGT M235T genotype partially explained inter-individual varia-tion in response to amlodipine among hypertensive patients of Jordanian Arab origin. Conclusion: It can be concluded that the AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with a higher efficacy. However, further multi-center studies with larger cohorts are needed to confirm these findings. conclusion: The AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with greater drug efficacy. However, further multi-central studies with larger cohorts are needed to confirm these findings.
- 9 March 2026
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 22 (3) , 1-6
The Variability of Response to Amlodipine and Its Relation with the Angiotensinogen M235T Genotype among a Sample of Hypertensive Patients in Jordan
Introduction: Amlodipine, a calcium channel blocker, is widely used to treat hyperten-sion, but its effectiveness varies among individuals. Clinicians have observed this variability, and previous research suggests that the Angiotensinogen (AGT) M235T genotype influences response to antihypertensive drugs like valsartan. This study investigates the association between the AGT M235T genetic variant and non-genetic anthropometric factors, and the response to amlodipine in essential hypertensive patients at the University of Jordan Hospital. Methods: A cohort of 46 unrelated Arabic Jordanian patients with essential hypertension was en-rolled. Baseline systolic and diastolic blood pressure (BP) readings were recorded before initiating 5 mg amlodipine, with follow-up measurements taken after one month. AGT M235T genotyping was performed using PCR-RFLP, and non-genetic data were obtained from hospital records. Results: It was found that 28.3% of the tested patients did not respond to amlodipine. The hetero-zygous AGT M235T genotype showed a significantly (p < 0.05, t-test) lower reduction in the BP compared to wild-type carriers, and its frequency was significantly higher (p < 0.05, ꭙ2 test) among the non-responders to amlodipine. In addition, the average age of the non-responders (41.5±10.3 years) was significantly (p < 0.05, t-test) lower than that of responders (47±10 years) to amlodipine. Discussion: The heterozygous AGT M235T genotype partially explained inter-individual varia-tion in response to amlodipine among hypertensive patients of Jordanian Arab origin. Conclusion: It can be concluded that the AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with a higher efficacy. However, further multi-center studies with larger cohorts are needed to confirm these findings. conclusion: The AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with greater drug efficacy. However, further multi-central studies with larger cohorts are needed to confirm these findings.
- Open Access
- 19 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 973
Functional Molecular Plasma Biomarkers of Inflammation and Repair in Kidney Disease Progression in Gum Arabica Modality of CKD
Using colorimetric ELISA, this study aims to assess the impact of Gum Arabica (GA) consumption on functional molecular plasma biomarkers of chronic kidney disease (CKD) via a prospective cohort of GA-consumers (cases) vs. non-consumer (age- and CKD stage-matched) controls. Cohort’s hypertension (92.5%), dyslipidemia (64.8%), and diabetes mellitus (54.8%) were prevalent; the mean CKD duration was 6.94 years (SD 7.8) for both study groups. Comparable eGFR, sCr, ESR, CRP, HbA1c, FPG, UA, and fasting lipid parameters were in both study arms. In consumer cases, the mean duration of GA-consumption was 1.3 ± 1.1 (range 0.25–6) years with a mean dose of 1.7 ± 1.0 (range 0.5–6) spoons per day. Leucine-rich alpha 2-glycoprotein, plasminogen activator inhibitor 1, sirtuin 1, and SOST–sclerostin 1 were significantly (p value < 0.01) of lower concentrations, but lipocalin 2 and uromodulin were invariably (p value < 0.05) greater in the GA-consumer cases than those of controls. Strikingly, cystatin C, myeloperoxidase, orosomucoid 1, and symmetric dimethylarginine lacked any substantial variations in the GA-consumer cases vs. those in controls (p value > 0.05). Proportional correlations of CKD duration–PAI1 levels and sCr-lipocalin 2 levels but inverse correlations of orosomucoid 1-hypertension duration and SDMA-DBP were evident in cases.
- 19 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 973
Open AccessFunctional Molecular Plasma Biomarkers of Inflammation and Repair in Kidney Disease Progression in Gum Arabica Modality of CKD
Using colorimetric ELISA, this study aims to assess the impact of Gum Arabica (GA) consumption on functional molecular plasma biomarkers of chronic kidney disease (CKD) via a prospective cohort of GA-consumers (cases) vs. non-consumer (age- and CKD stage-matched) controls. Cohort’s hypertension (92.5%), dyslipidemia (64.8%), and diabetes mellitus (54.8%) were prevalent; the mean CKD duration was 6.94 years (SD 7.8) for both study groups. Comparable eGFR, sCr, ESR, CRP, HbA1c, FPG, UA, and fasting lipid parameters were in both study arms. In consumer cases, the mean duration of GA-consumption was 1.3 ± 1.1 (range 0.25–6) years with a mean dose of 1.7 ± 1.0 (range 0.5–6) spoons per day. Leucine-rich alpha 2-glycoprotein, plasminogen activator inhibitor 1, sirtuin 1, and SOST–sclerostin 1 were significantly (p value < 0.01) of lower concentrations, but lipocalin 2 and uromodulin were invariably (p value < 0.05) greater in the GA-consumer cases than those of controls. Strikingly, cystatin C, myeloperoxidase, orosomucoid 1, and symmetric dimethylarginine lacked any substantial variations in the GA-consumer cases vs. those in controls (p value > 0.05). Proportional correlations of CKD duration–PAI1 levels and sCr-lipocalin 2 levels but inverse correlations of orosomucoid 1-hypertension duration and SDMA-DBP were evident in cases.
- Open Access
- 24 October 2025
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 23 (3) , 1-17
Combinatorial Multiplicity of Cardiometabolic and Inflammatory Markers in Gum Arabica Modality of CKD CAM: Part 2
AIM: A combinatorial multiplicity of molecular blood markers were assessed using ELISA colorimetric determinations in this prospective cohort study of the impact of guar gum arabica (GA) use on kidney function parameters of chronic kidney disease (CKD) in consumers (cases) vs. non consumers (age- and CKD stage- matched controls). RESULTS: Mean age of study participants was 68.12 (±SD 10) years with homogenous sex distribution in both study arms and comparable levels of eGFR, sCr, ESR, CRP, HbA1c, FPG, UA and fasting lipid profiling parameters (P value >0.05). Consistently in study population of recruits; mean CKD duration was 6.94 years (±SD 7.8) and CKD stage IV (37.6% of total study population) was of predominant incidence, followed by stages IIIa and IIIb (20.4% and 19.4%, respectively). Despite the negative glucosuria in 75% of CKD patients; hypertension (92.5%), dyslipidemia (64.8%) and diabetes mellitus (54.8%) were prevalent in a descending order of predominance. GA consumption mean duration was 1.3±1.1 (range 0.25-6) years with a mean dose of 1.7±1.0 (range 0.5-6) spoons per day. Substantially plasma concentrations of resistin (P value =0.047), and nesfatin-1 in cases were substantially greater (P value =0.005) but obestatin (P value =0.018), kisspeptin (P value =0.006), and vascular endothelial growth factor (VEGF) (P value =0.003) were found of pronouncedly lower blood levels in cases in comparison to those of controls. Invariably, human asymmetric dimethylarginine (ADMA), zinc alpha 2-glycoprtein, alpha klotho, ghrelin, and C-reactive protein (CRP) lacked any significant discrepancies in plasma levels in cases vs. those of controls (P value >0.05). In CKD cases on GA modality, ghrelin had substantial inverse correlations with dialysis duration, FBS and uric acid in CKD cases. Pronounced proportional associations of sCr levels were found with ghrelin, hsCRP and resistin in the same pool of cases. eGFR disproportionally correlated with cases’ hsCRP and resistin. In GA-naïve-CKD controls; sCr related proportionally and significantly with asymmetric dimethylarginine (ADMA) and Zinc alpha 2-glycoprtein. CONCLUSIVELY: interventional studies are much justifiably needed.
- 24 October 2025
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 23 (3) , 1-17
Open AccessCombinatorial Multiplicity of Cardiometabolic and Inflammatory Markers in Gum Arabica Modality of CKD CAM: Part 2
AIM: A combinatorial multiplicity of molecular blood markers were assessed using ELISA colorimetric determinations in this prospective cohort study of the impact of guar gum arabica (GA) use on kidney function parameters of chronic kidney disease (CKD) in consumers (cases) vs. non consumers (age- and CKD stage- matched controls). RESULTS: Mean age of study participants was 68.12 (±SD 10) years with homogenous sex distribution in both study arms and comparable levels of eGFR, sCr, ESR, CRP, HbA1c, FPG, UA and fasting lipid profiling parameters (P value >0.05). Consistently in study population of recruits; mean CKD duration was 6.94 years (±SD 7.8) and CKD stage IV (37.6% of total study population) was of predominant incidence, followed by stages IIIa and IIIb (20.4% and 19.4%, respectively). Despite the negative glucosuria in 75% of CKD patients; hypertension (92.5%), dyslipidemia (64.8%) and diabetes mellitus (54.8%) were prevalent in a descending order of predominance. GA consumption mean duration was 1.3±1.1 (range 0.25-6) years with a mean dose of 1.7±1.0 (range 0.5-6) spoons per day. Substantially plasma concentrations of resistin (P value =0.047), and nesfatin-1 in cases were substantially greater (P value =0.005) but obestatin (P value =0.018), kisspeptin (P value =0.006), and vascular endothelial growth factor (VEGF) (P value =0.003) were found of pronouncedly lower blood levels in cases in comparison to those of controls. Invariably, human asymmetric dimethylarginine (ADMA), zinc alpha 2-glycoprtein, alpha klotho, ghrelin, and C-reactive protein (CRP) lacked any significant discrepancies in plasma levels in cases vs. those of controls (P value >0.05). In CKD cases on GA modality, ghrelin had substantial inverse correlations with dialysis duration, FBS and uric acid in CKD cases. Pronounced proportional associations of sCr levels were found with ghrelin, hsCRP and resistin in the same pool of cases. eGFR disproportionally correlated with cases’ hsCRP and resistin. In GA-naïve-CKD controls; sCr related proportionally and significantly with asymmetric dimethylarginine (ADMA) and Zinc alpha 2-glycoprtein. CONCLUSIVELY: interventional studies are much justifiably needed.
- Open Access
- 16 April 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70611
Variability in Response to Valsartan and Its Relationship With AGT M235T Genotype and Other Nongenetic Parameters Among a Sample of Hypertensive Individuals in Jordan: A Prospective Pilot Study
Background: Valsartan, an angiotensin receptor antagonist widely used in hypertension and heart failure management, exhibits noticeable interindividual variation in response among hypertensive patients at the University of Jordan Hospital. The angiotensinogen (AGT) gene variant M235T, a functional genetic variant, influences the renin‐angiotensin system.Aims: This study aims to explore interindividual variations in the valsartan response, considering genetics, particularly the AGT M235T variant, and other nongenetic factors.Methods: This cohort study involved 95 unrelated Arabic Jordanians diagnosed with essential hypertension. Systolic (SBP) and diastolic blood pressure (DBP) measurements were taken at the initiation of 160 mg valsartan and after 1 month of treatment, assessing the valsartan response for each patient. Genetic analysis of AGT M235T was done using the polymerase chain reaction‐restriction fragment length polymorphism genotyping method. Anthropometric data were collected from University of Jordan Hospital computer records.Results: Valsartan response assessment revealed diverse individual responses, the response to valsartan varied, with SBP reductions from < 10 to > 70 mmHg and DBP from < 2 to 30 mmHg. Patients with homozygous AGT M235T genotypes showed a less significant response (p < 0.05) to valsartan than heterozygous and reference genotypes. Additionally, results indicated a positive correlation of age (p = 0.03) and a negative correlation of height (p = 0.02–0.04) with the valsartan response. Regression analysis demonstrated that the patients' sex significantly influenced the valsartan response (p < 0.05).Conclusions: This study identifies the AGT M235T genotype as a potential genetic contributor to variability in the valsartan response. Associations with age, height, and sex underscore the importance of considering genetic and demographic factors in tailoring valsartan therapy, for advancing personalized hypertension management.
- 16 April 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70611
Open AccessVariability in Response to Valsartan and Its Relationship With AGT M235T Genotype and Other Nongenetic Parameters Among a Sample of Hypertensive Individuals in Jordan: A Prospective Pilot Study
Background: Valsartan, an angiotensin receptor antagonist widely used in hypertension and heart failure management, exhibits noticeable interindividual variation in response among hypertensive patients at the University of Jordan Hospital. The angiotensinogen (AGT) gene variant M235T, a functional genetic variant, influences the renin‐angiotensin system.Aims: This study aims to explore interindividual variations in the valsartan response, considering genetics, particularly the AGT M235T variant, and other nongenetic factors.Methods: This cohort study involved 95 unrelated Arabic Jordanians diagnosed with essential hypertension. Systolic (SBP) and diastolic blood pressure (DBP) measurements were taken at the initiation of 160 mg valsartan and after 1 month of treatment, assessing the valsartan response for each patient. Genetic analysis of AGT M235T was done using the polymerase chain reaction‐restriction fragment length polymorphism genotyping method. Anthropometric data were collected from University of Jordan Hospital computer records.Results: Valsartan response assessment revealed diverse individual responses, the response to valsartan varied, with SBP reductions from < 10 to > 70 mmHg and DBP from < 2 to 30 mmHg. Patients with homozygous AGT M235T genotypes showed a less significant response (p < 0.05) to valsartan than heterozygous and reference genotypes. Additionally, results indicated a positive correlation of age (p = 0.03) and a negative correlation of height (p = 0.02–0.04) with the valsartan response. Regression analysis demonstrated that the patients' sex significantly influenced the valsartan response (p < 0.05).Conclusions: This study identifies the AGT M235T genotype as a potential genetic contributor to variability in the valsartan response. Associations with age, height, and sex underscore the importance of considering genetic and demographic factors in tailoring valsartan therapy, for advancing personalized hypertension management.
- Open Access
- 29 February 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (3) , 273
The Association of M235T Genetic Polymorphism in Angiotensinogen Gene and Other Non-Genetic Factors with Essential Hypertension among Jordanian Patients
Background: Hypertension, characterized by elevated pressure, poses a significant health risk. Recent studies in Jordan highlight high hypertension rates, emphasizing the need for genetic investigations to comprehend essential hypertension determinants. The AGT gene, part of the Renin Angiotensin System, is linked to blood pressure regulation. Limited information exists on the frequency of this polymorphism among Jordanian hypertensive patients. Aims: This study explores the association between the AGT M235T polymorphism and essential hypertension in Jordan. Methods: A cross-sectional study with 435 participants (199 hypertensive, 236 non-hypertensive) was conducted at the University of Jordan Hospital. Blood pressure was measured, and genetic analysis of the AGT M235T polymorphism was completed using the PCR-RFLP technique. Chi-square and t-tests were used for comparisons using SPSS software. Results: Hypertensive patients exhibited significantly higher weight, BMI, and blood pressure. Genotyping results showed no significant difference (p > 0.05, Chi-square) in AGT M235T polymorphism distribution between control and patient groups. In addition, allele frequencies showed comparable patterns (p > 0.05, Chi-square). All genotype frequencies showed no deviation from the Hardy–Weinberg equation (p > 0.05, Chi-square). Conclusions: The AGT M235T genetic polymorphism is not more prevalent among hypertensive patients in Jordan, although the average weight and BMI among hypertensive patients is higher than the non-hypertensive participants. Obesity can be addressed as a potential risk factor for essential hypertension in Jordan. In addition, it is recommended to find out the influence of the AGT M235T genetic polymorphism on the response of antihypertensive drugs among hypertensive patients in Jordan.
- 29 February 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (3) , 273
Open AccessThe Association of M235T Genetic Polymorphism in Angiotensinogen Gene and Other Non-Genetic Factors with Essential Hypertension among Jordanian Patients
Background: Hypertension, characterized by elevated pressure, poses a significant health risk. Recent studies in Jordan highlight high hypertension rates, emphasizing the need for genetic investigations to comprehend essential hypertension determinants. The AGT gene, part of the Renin Angiotensin System, is linked to blood pressure regulation. Limited information exists on the frequency of this polymorphism among Jordanian hypertensive patients. Aims: This study explores the association between the AGT M235T polymorphism and essential hypertension in Jordan. Methods: A cross-sectional study with 435 participants (199 hypertensive, 236 non-hypertensive) was conducted at the University of Jordan Hospital. Blood pressure was measured, and genetic analysis of the AGT M235T polymorphism was completed using the PCR-RFLP technique. Chi-square and t-tests were used for comparisons using SPSS software. Results: Hypertensive patients exhibited significantly higher weight, BMI, and blood pressure. Genotyping results showed no significant difference (p > 0.05, Chi-square) in AGT M235T polymorphism distribution between control and patient groups. In addition, allele frequencies showed comparable patterns (p > 0.05, Chi-square). All genotype frequencies showed no deviation from the Hardy–Weinberg equation (p > 0.05, Chi-square). Conclusions: The AGT M235T genetic polymorphism is not more prevalent among hypertensive patients in Jordan, although the average weight and BMI among hypertensive patients is higher than the non-hypertensive participants. Obesity can be addressed as a potential risk factor for essential hypertension in Jordan. In addition, it is recommended to find out the influence of the AGT M235T genetic polymorphism on the response of antihypertensive drugs among hypertensive patients in Jordan.
- 6 September 2023
- Published by Medknow in Indian Journal of Transplantation
- Vol. 18 (1) , 55-57
Generic Tacrolimus in Kidney Transplant Patients at Jordan University Hospital
Background: Tacrolimus is the immunosuppressive drug of choice for kidney transplant patients, but its cost is very high in the total drug cost for patients with renal disease. Lower drug costs can be achieved with generic tacrolimus. For this reason, the Ministry of Health mandated to implementation of a switch to generic form and so we wanted to evaluate whether a switch could be safely performed and to observe the effect of this on kidney function. Subjects and Methods: In this observational study, 28 stable kidney transplant patients taking Prograf®(Astellas) were switched to a generic Pangraf®(Pancea) in a 1:1 dose ratio and were followed up for 6 months. Plasma creatinine levels and trough concentrations of tacrolimus were recorded three times on Prograf® and weekly for 4 weeks, then monthly after conversion to Pangraf®. Results: Tacrolimus mean C0 levels were 6.97 ± 0.92 ng/mL before and 7.4 ± 1.23 ng/mL after conversion (P = 0.22). Mean serum creatinine values were 1.13 ± 0.53 mg/dL and 1.15 ± 0.54 mg/dL before and after conversion, respectively (P = 0.27). Conclusion: Switching from branded tacrolimus to generic tacrolimus seems possible and safe, but close monitoring is essential.
- 6 September 2023
- Published by Medknow in Indian Journal of Transplantation
- Vol. 18 (1) , 55-57
Generic Tacrolimus in Kidney Transplant Patients at Jordan University Hospital
Background: Tacrolimus is the immunosuppressive drug of choice for kidney transplant patients, but its cost is very high in the total drug cost for patients with renal disease. Lower drug costs can be achieved with generic tacrolimus. For this reason, the Ministry of Health mandated to implementation of a switch to generic form and so we wanted to evaluate whether a switch could be safely performed and to observe the effect of this on kidney function. Subjects and Methods: In this observational study, 28 stable kidney transplant patients taking Prograf®(Astellas) were switched to a generic Pangraf®(Pancea) in a 1:1 dose ratio and were followed up for 6 months. Plasma creatinine levels and trough concentrations of tacrolimus were recorded three times on Prograf® and weekly for 4 weeks, then monthly after conversion to Pangraf®. Results: Tacrolimus mean C0 levels were 6.97 ± 0.92 ng/mL before and 7.4 ± 1.23 ng/mL after conversion (P = 0.22). Mean serum creatinine values were 1.13 ± 0.53 mg/dL and 1.15 ± 0.54 mg/dL before and after conversion, respectively (P = 0.27). Conclusion: Switching from branded tacrolimus to generic tacrolimus seems possible and safe, but close monitoring is essential.
- Open Access
- 30 March 2021
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 22 (1) , 225-229
Accuracy and feasibility of portable blood pressure monitoring in the detection of atrial fibrillation in hemodialysis patients
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in clinical practice and is a common comorbidity in hemodialysis patients. AF contributes to cardiovascular complications; therefore, it is recommended to screen for AF in high-risk patients to prevent serious complications. As we currently lack a handy AF screening tool, the aim of this study was to assess the accuracy of a modified BP monitor (Omron M6), in detecting AF in hemodialysis patients. In a cross-sectional analysis conducted from October 2018 to February 2019, we enrolled all the hemodialysis patients, older than 18 years and maintained on hemodialysis for at least 3 months in four hemodialysis centers in Jordan. Logistic regression was used to predict the accuracy, while the R package (epiR) was used to determine the sensitivity and specificity of the Omron M6 in screening AF. A total of 227 patients participated in the study, with a median age of 57 years (42.8-67.3); among these, 44.5% were female. Of all the participants, 18 were detected with AF, which was confirmed by a 12-lead ECG. The prevalence of AF in our study was 7.9%, while the sensitivity, specificity and accuracy of the Omron M6 in detecting AF were calculated as 83.0% (95% CI, 59.0-96.0), 94.0% (95% CI, 90.0-97.0) and 93.4% (95% CI, 88.0-95.0) respectively. We concluded that Omron M6 has high sensitivity, specificity, and accuracy in screening AF among hemodialysis patients. However, further studies are required to ascertain and firmly establish this preliminary finding.
- 30 March 2021
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 22 (1) , 225-229
Open AccessAccuracy and feasibility of portable blood pressure monitoring in the detection of atrial fibrillation in hemodialysis patients
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in clinical practice and is a common comorbidity in hemodialysis patients. AF contributes to cardiovascular complications; therefore, it is recommended to screen for AF in high-risk patients to prevent serious complications. As we currently lack a handy AF screening tool, the aim of this study was to assess the accuracy of a modified BP monitor (Omron M6), in detecting AF in hemodialysis patients. In a cross-sectional analysis conducted from October 2018 to February 2019, we enrolled all the hemodialysis patients, older than 18 years and maintained on hemodialysis for at least 3 months in four hemodialysis centers in Jordan. Logistic regression was used to predict the accuracy, while the R package (epiR) was used to determine the sensitivity and specificity of the Omron M6 in screening AF. A total of 227 patients participated in the study, with a median age of 57 years (42.8-67.3); among these, 44.5% were female. Of all the participants, 18 were detected with AF, which was confirmed by a 12-lead ECG. The prevalence of AF in our study was 7.9%, while the sensitivity, specificity and accuracy of the Omron M6 in detecting AF were calculated as 83.0% (95% CI, 59.0-96.0), 94.0% (95% CI, 90.0-97.0) and 93.4% (95% CI, 88.0-95.0) respectively. We concluded that Omron M6 has high sensitivity, specificity, and accuracy in screening AF among hemodialysis patients. However, further studies are required to ascertain and firmly establish this preliminary finding.
- 15 September 2020
- Published by Bentham Science Publishers Ltd. in Current Respiratory Medicine Reviews
- Vol. 16 (1) , 34-38
Long-term Effects of Gastric Bypass Surgery in Patients with Obstructive Sleep Apnea
Background: Obstructive sleep apnea is a common disorder involving, intermittent mechanical obstruction of the upper airway during sleep. Obesity is the most powerful risk factor for obstructive sleep apnea. Objective: This study aimed to investigate the long-term effect of Roux-en-Y gastric bypass bariatric surgery on patients with obstructive sleep apnea. Methods: This study included patients were referred for bariatric surgery (Roux-en-Y gastric bypass) to control symptoms and complications of obesity during a 5-year period. An overnight sleep study was performed for each patient before and after the bariatric surgery, to study its effect on different obstructive sleep apnea-related variables. Results: This study included 179 patients (mean age 35.9 ± 10.7 years). The mean duration from preoperative assessment to postoperative assessment was 2.4 ± 2.2 years. The mean change in body mass index and weight showed a decrease of 16.0 ± 16.0 kg/m2 and48.7 ± 25.9 kg, respectively. The apnea hypopnea index decreased by a mean of 22.6 ± 26.3 events/hour. Conclusion: We concluded that a decrease in the body mass index by 1 kg/m2 could predict a decrease in the apnea hypopnea index by 0.46 events/hour. Moreover, after mean follow-up duration of 2.4 years, 84.3% of mild and 83.3% of moderate obstructive sleep apnea patients became normal postoperatively.
- 15 September 2020
- Published by Bentham Science Publishers Ltd. in Current Respiratory Medicine Reviews
- Vol. 16 (1) , 34-38
Long-term Effects of Gastric Bypass Surgery in Patients with Obstructive Sleep Apnea
Background: Obstructive sleep apnea is a common disorder involving, intermittent mechanical obstruction of the upper airway during sleep. Obesity is the most powerful risk factor for obstructive sleep apnea. Objective: This study aimed to investigate the long-term effect of Roux-en-Y gastric bypass bariatric surgery on patients with obstructive sleep apnea. Methods: This study included patients were referred for bariatric surgery (Roux-en-Y gastric bypass) to control symptoms and complications of obesity during a 5-year period. An overnight sleep study was performed for each patient before and after the bariatric surgery, to study its effect on different obstructive sleep apnea-related variables. Results: This study included 179 patients (mean age 35.9 ± 10.7 years). The mean duration from preoperative assessment to postoperative assessment was 2.4 ± 2.2 years. The mean change in body mass index and weight showed a decrease of 16.0 ± 16.0 kg/m2 and48.7 ± 25.9 kg, respectively. The apnea hypopnea index decreased by a mean of 22.6 ± 26.3 events/hour. Conclusion: We concluded that a decrease in the body mass index by 1 kg/m2 could predict a decrease in the apnea hypopnea index by 0.46 events/hour. Moreover, after mean follow-up duration of 2.4 years, 84.3% of mild and 83.3% of moderate obstructive sleep apnea patients became normal postoperatively.
- 1 December 2019
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 178 (12) , 942-946
Postinfectious glomerulonephritis: a cause of pulmonary renal syndrome
- 1 December 2019
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 178 (12) , 942-946
Postinfectious glomerulonephritis: a cause of pulmonary renal syndrome
- Open Access
- 28 July 2019
- Published by International Medical Publisher (Fundacion de Neurociencias) in The International Arabic Journal of Antimicrobial Agents
- Vol. 9 (3)
Prevalence of Bacterial Lower Respiratory Tract Infections at a Tertiary Hospital in Jordan
Background: Lower respiratory tract infections (LRTI) are a major cause of morbidity and mortality globally. The World Health Organization (WHO) estimates that LRTI are the most common global cause of death from infectious diseases. However, the specific etiologic agent associated with LRTI is often unknown. Aims: We determined the bacterial infections and seasonal patterns associated with LRTI among hospitalized cases at Jordan University Hospital (JUH) for a period of five years. Methods: We conducted a multi-year study among hospitalized patients in Jordan on LRTI-associated bacterial etiology. Results: We found bacterial infections among 105 (21.1%) out of 495 LRTI patients. The most frequently identified bacteria in the LRTI patients were Staphylococcus aureus (7.7%) followed by Pseudomonas aeruginosa (5.1%). Most of the LRTI patients (95.2%) had at least one chronic disease and many were admitted to the Intensive Care Unit (16.8%). Of the 18 (3.64%) patients with LRTI who died at the hospital, 2 had a bacterial infection. We noticed a seasonal pattern of bacterial infections, with the highest prevalence during the winter months. Conclusions: Our findings suggest that early identification of bacterial agents and control of chronic disease may improve clinical management and reduce morbidity and mortality from LRTI.
- 28 July 2019
- Published by International Medical Publisher (Fundacion de Neurociencias) in The International Arabic Journal of Antimicrobial Agents
- Vol. 9 (3)
Open AccessPrevalence of Bacterial Lower Respiratory Tract Infections at a Tertiary Hospital in Jordan
Background: Lower respiratory tract infections (LRTI) are a major cause of morbidity and mortality globally. The World Health Organization (WHO) estimates that LRTI are the most common global cause of death from infectious diseases. However, the specific etiologic agent associated with LRTI is often unknown. Aims: We determined the bacterial infections and seasonal patterns associated with LRTI among hospitalized cases at Jordan University Hospital (JUH) for a period of five years. Methods: We conducted a multi-year study among hospitalized patients in Jordan on LRTI-associated bacterial etiology. Results: We found bacterial infections among 105 (21.1%) out of 495 LRTI patients. The most frequently identified bacteria in the LRTI patients were Staphylococcus aureus (7.7%) followed by Pseudomonas aeruginosa (5.1%). Most of the LRTI patients (95.2%) had at least one chronic disease and many were admitted to the Intensive Care Unit (16.8%). Of the 18 (3.64%) patients with LRTI who died at the hospital, 2 had a bacterial infection. We noticed a seasonal pattern of bacterial infections, with the highest prevalence during the winter months. Conclusions: Our findings suggest that early identification of bacterial agents and control of chronic disease may improve clinical management and reduce morbidity and mortality from LRTI.